lipofuscinosis

(redirected from ceroid lipofuscinosis)
Also found in: Medical.
Translations

lip·o·fus·ci·no·sis

n. lipofuscinosis, almacenamiento anormal de cualquiera de los pigmentos adiposos.
References in periodicals archive ?
Davidson's team focused on the rare, inherited childhood disorder, late infantile neuronal ceroid lipofuscinosis, also called Batten disease.
A postmortem diagnosis of neuronal ceroid lipofuscinosis (NCL) was made based on the presence of neuronal granular cytoplasmic material that was autofluorescent and stained with periodic acid Schiff and Luxol fast blue.
It is the most common form of a group of disorders called neuronal ceroid lipofuscinosis (or NCLs).
The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter.
AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis.
Palo Alto, CA, announced it has received approval from the Institutional Review Board (IRB) of the Oregon Health & Science University (OHSU), Portland, OR, to initiate a Phase I clinical trial of the company's proprietary human neural stem cell product - HuCNS-SC - to treat infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten disease.
Niemann-Pick type C, Tay-Sachs, Sandhoff's); other storage disorders (neuronal ceroid lipofuscinosis, neuronal brain iron accumulation type 1, Wilson's disease, Lafora body disease); Baltic myoclonus; spinocerebellar ataxias or SCAs; dentatorubropallidoluysian atrophy (DRPLA); multiple sclerosis; and certain mitochondrial disorders;
StemCells has completed a Phase I clinical trial of its HuCNS-SC cells for the treatment of Neuronal Ceroid Lipofuscinosis (NCL), a fatal brain disorder in children.
The proposed Phase 1 trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC for the treatment of infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), the most severe forms of a group of disorders commonly referred to as Batten disease.
Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis.
StemCells has completed a Phase I clinical trial of its HuCNS-SC cells for the treatment of a Neuronal Ceroid Lipofuscinosis (NCL), a fatal brain disorder in children.
Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is an autosomal recessive genetic disorder that causes degeneration of the central nervous system.